$0.9627
+0.09
(+10.66%)▲
Insights on Gritstone Oncology Inc
Revenue is down for the last 2 quarters, 1.56M → 29.0K (in $), with an average decrease of 98.2% per quarter
Netprofit is up for the last 2 quarters, -38.43M → -30.81M (in $), with an average increase of 24.7% per quarter
In the last 1 year, Novo Nordisk A/s has given 50.8% return, outperforming this stock by 112.6%
In the last 3 years, Novo Nordisk A/s has given 231.7% return, outperforming this stock by 319.9%
8.75%
Downside
Day's Volatility :11.44%
Upside
2.95%
30.04%
Downside
52 Weeks Volatility :79.83%
Upside
71.17%
Period | Gritstone Oncology Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -57.4% | -2.2% | 0.0% |
6 Months | -47.39% | 9.8% | 0.0% |
1 Year | -60.55% | 5.4% | 0.5% |
3 Years | -88.16% | 14.3% | -21.1% |
Market Capitalization | 81.3M |
Book Value | $0.53 |
Earnings Per Share (EPS) | -1.2 |
Wall Street Target Price | 5.17 |
Profit Margin | 0.0% |
Operating Margin TTM | -293.47% |
Return On Assets TTM | -41.7% |
Return On Equity TTM | -124.41% |
Revenue TTM | 16.3M |
Revenue Per Share TTM | 0.14 |
Quarterly Revenue Growth YOY | 143.6% |
Gross Profit TTM | -91.5M |
EBITDA | -132.0M |
Diluted Eps TTM | -1.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.01 |
EPS Estimate Next Year | -0.96 |
EPS Estimate Current Quarter | -0.33 |
EPS Estimate Next Quarter | -0.33 |
What analysts predicted
Upside of 437.03%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.2M | - |
Net Income | -64.8M | ↑ 56.55% |
Net Profit Margin | -5.5K% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.4M | ↑ 267.73% |
Net Income | -90.9M | ↑ 40.37% |
Net Profit Margin | -2.1K% | ↑ 3373.96% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 4.0M | ↓ 7.51% |
Net Income | -104.6M | ↑ 15.05% |
Net Profit Margin | -2.6K% | ↓ 508.24% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 46.7M | ↑ 1057.22% |
Net Income | -75.0M | ↓ 28.35% |
Net Profit Margin | -160.44% | ↑ 2430.87% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 9.3M | ↓ 80.16% |
Net Income | -113.1M | ↑ 50.93% |
Net Profit Margin | -1.2K% | ↓ 1060.05% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 1.3M | ↓ 85.64% |
Net Income | -138.5M | ↑ 22.42% |
Net Profit Margin | -10.4K% | ↓ 9184.47% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 436.0K | ↓ 84.21% |
Net Income | -30.1M | ↑ 2.9% |
Net Profit Margin | -6.9K% | ↓ 5835.44% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.3M | ↑ 204.36% |
Net Income | -30.7M | ↑ 2.02% |
Net Profit Margin | -2.3K% | ↑ 4582.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 542.0K | ↓ 59.16% |
Net Income | -34.0M | ↑ 10.86% |
Net Profit Margin | -6.3K% | ↓ 3961.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 400.0K | ↓ 26.2% |
Net Income | -35.3M | ↑ 3.72% |
Net Profit Margin | -8.8K% | ↓ 2542.41% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.6M | ↑ 291.25% |
Net Income | -38.4M | ↑ 9.01% |
Net Profit Margin | -2.5K% | ↑ 6358.15% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 29.0K | ↓ 98.15% |
Net Income | -30.8M | ↓ 19.82% |
Net Profit Margin | -106.3K% | ↓ 103813.12% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 189.6M | ↑ 61.6% |
Total Liabilities | 40.4M | ↑ 102.0% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 184.4M | ↓ 2.73% |
Total Liabilities | 50.0M | ↑ 23.76% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 221.6M | ↑ 20.16% |
Total Liabilities | 54.8M | ↑ 9.56% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 278.1M | ↑ 25.52% |
Total Liabilities | 62.0M | ↑ 13.12% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 240.8M | ↓ 13.43% |
Total Liabilities | 70.0M | ↑ 12.82% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 177.8M | ↓ 26.16% |
Total Liabilities | 125.9M | ↑ 79.95% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 205.2M | ↓ 4.07% |
Total Liabilities | 68.4M | ↑ 35.23% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 240.8M | ↑ 17.3% |
Total Liabilities | 70.0M | ↑ 2.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 210.0M | ↓ 12.79% |
Total Liabilities | 69.1M | ↓ 1.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 222.6M | ↑ 6.04% |
Total Liabilities | 113.1M | ↑ 63.67% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 187.2M | ↓ 15.9% |
Total Liabilities | 113.2M | ↑ 0.16% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 177.8M | ↓ 5.05% |
Total Liabilities | 125.9M | ↑ 11.2% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -38.2M | ↑ 9.12% |
Investing Cash Flow | -59.1M | ↑ 77.74% |
Financing Cash Flow | 110.4M | ↑ 15.27% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -85.0M | ↑ 122.76% |
Investing Cash Flow | 15.8M | ↓ 126.8% |
Financing Cash Flow | 74.4M | ↓ 32.64% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -89.1M | ↑ 4.81% |
Investing Cash Flow | 65.9M | ↑ 316.32% |
Financing Cash Flow | 135.8M | ↑ 82.54% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -50.7M | ↓ 43.12% |
Investing Cash Flow | -118.6M | ↓ 279.76% |
Financing Cash Flow | 108.8M | ↓ 19.91% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -115.9M | ↑ 128.79% |
Investing Cash Flow | -13.0M | ↓ 89.06% |
Financing Cash Flow | 83.1M | ↓ 23.6% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.8M | ↓ 2.1% |
Investing Cash Flow | 3.1M | ↓ 86.32% |
Financing Cash Flow | 19.3M | ↑ 6138.71% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.4M | ↑ 17.8% |
Investing Cash Flow | -46.2M | ↓ 1600.88% |
Financing Cash Flow | 64.4M | ↑ 232.81% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -40.1M | ↑ 31.99% |
Investing Cash Flow | 21.2M | ↓ 145.88% |
Financing Cash Flow | 8.6M | ↓ 86.57% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -31.0M | ↓ 22.77% |
Investing Cash Flow | 24.6M | ↑ 16.15% |
Financing Cash Flow | 1.0M | ↓ 88.24% |
Sell
Neutral
Buy
Gritstone Oncology Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Gritstone Oncology Inc | -4.68% | -47.39% | -60.55% | -88.16% | -91.4% |
Moderna, Inc. | 18.95% | 73.44% | -5.12% | -22.12% | 361.25% |
Regeneron Pharmaceuticals, Inc. | 1.97% | 14.97% | 27.24% | 91.91% | 178.01% |
Novo Nordisk A/s | -3.46% | 21.74% | 46.11% | 231.67% | 415.39% |
Vertex Pharmaceuticals Incorporated | -0.78% | 3.97% | 16.56% | 88.16% | 129.5% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Gritstone Oncology Inc | NA | NA | NA | -1.01 | -1.24 | -0.42 | NA | 0.53 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Gritstone Oncology Inc | Buy | $81.3M | -91.4% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 361.25% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.01% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 415.39% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 129.5% | 28.81 | 36.68% |
Redmile Group, LLC
Point72 Asset Management, L.P.
BlackRock Inc
Morgan Stanley - Brokerage Accounts
Vanguard Group Inc
Versant Venture Management LLC
Gritstone Oncology Inc’s price-to-earnings ratio stands at None
Read Moregritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
Organization | Gritstone Oncology Inc |
Employees | 231 |
CEO | Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. |
Industry | Health Technology |